GRIFOLS S A/S (NASDAQ:GRFS) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports.

According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “

A number of other brokerages have also commented on GRFS. JPMorgan Chase & Co. raised GRIFOLS S A/S from a neutral rating to an overweight rating and upped their price objective for the company from $21.00 to $22.50 in a report on Thursday, June 27th. ValuEngine lowered GRIFOLS S A/S from a hold rating to a sell rating in a report on Thursday, August 1st. Finally, BidaskClub lowered GRIFOLS S A/S from a strong-buy rating to a buy rating in a report on Tuesday, August 20th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $20.75.

GRFS stock opened at $21.42 on Wednesday. The company has a current ratio of 2.68, a quick ratio of 0.95 and a debt-to-equity ratio of 1.38. The firm has a market capitalization of $15.04 billion, a PE ratio of 18.31, a PEG ratio of 1.35 and a beta of 1.11. GRIFOLS S A/S has a 1-year low of $17.42 and a 1-year high of $23.03. The business’s 50 day simple moving average is $22.02 and its 200 day simple moving average is $19.88.

Hedge funds and other institutional investors have recently modified their holdings of the business. First Trust Advisors LP grew its holdings in GRIFOLS S A/S by 9.7% in the 1st quarter. First Trust Advisors LP now owns 5,125,719 shares of the biotechnology company’s stock valued at $103,078,000 after buying an additional 453,032 shares in the last quarter. Marshall Wace LLP grew its holdings in GRIFOLS S A/S by 628.4% in the 1st quarter. Marshall Wace LLP now owns 133,498 shares of the biotechnology company’s stock valued at $2,685,000 after buying an additional 115,170 shares in the last quarter. CIBC Asset Management Inc grew its holdings in GRIFOLS S A/S by 79.6% in the 1st quarter. CIBC Asset Management Inc now owns 210,981 shares of the biotechnology company’s stock valued at $4,243,000 after buying an additional 93,510 shares in the last quarter. Todd Asset Management LLC grew its holdings in GRIFOLS S A/S by 3.1% in the 1st quarter. Todd Asset Management LLC now owns 879,670 shares of the biotechnology company’s stock valued at $17,690,000 after buying an additional 26,467 shares in the last quarter. Finally, Quadrant Capital Group LLC grew its holdings in GRIFOLS S A/S by 24.8% in the 2nd quarter. Quadrant Capital Group LLC now owns 20,324 shares of the biotechnology company’s stock valued at $422,000 after buying an additional 4,033 shares in the last quarter. 18.00% of the stock is currently owned by hedge funds and other institutional investors.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: How to calculate the intrinsic value of a stock

Get a free copy of the Zacks research report on GRIFOLS S A/S (GRFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.